Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Elobixibat
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Albireo Reports Topline Results from Phase 2 Trial of Elobixibat in NAFLD/NASH
Details : Following promising results in preclinical studies, the Phase 2 study achieved the primary endpoint of reduction of low-density lipoprotein cholesterol (LDL-C) but did not achieve proof-of-concept for other key NASH measures.
Brand Name : Goofice
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 18, 2020
Lead Product(s) : Elobixibat
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Elobixibat
Therapeutic Area : Gastroenterology
Study Phase : Approved
Sponsor : Hercules Capital
Deal Size : $105.0 million
Deal Type : Financing
Albireo Announces Two Financing Transactions to Extend Cash Runway Into the Beginning of 2022
Details : These funding arrangements with new and existing partners provide the company additional flexibility and cash runway into the beginning of 2022, past the planned approval and commercial launch of odevixibat for the treatment of progressive familial intra...
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : $10.0 million
June 09, 2020
Lead Product(s) : Elobixibat
Therapeutic Area : Gastroenterology
Highest Development Status : Approved
Sponsor : Hercules Capital
Deal Size : $105.0 million
Deal Type : Financing
Lead Product(s) : Elobixibat
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Albireo Completes Enrollment in Phase 2 Study of Elobixibat in NASH/NAFLD
Details : Trial enrolled 47 patients, and is designed to assess the safety and efficacy of a once-daily 5mg dose of elobixibat over 16 weeks in adult patients across 10 U.S. sites with biopsy-confirmed NASH.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 10, 2020
Lead Product(s) : Elobixibat
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?